Despite the unquestionable success of trastuzumab and other anti-HER2 agents in the treatment of HER2-positive breast cancer, resistance to these therapies is still a major problem in the metastatic setting.
We are currently working on different projects aimed to:
Uncover novel candidate genes responsible for resistance to trastuzumab, lapatinib, or the combination of both through in vitro and in vivo models
Analyze tissue samples from HER2 positive breast cancer patients (who received anti-HER2 therapy) to uncover novel (or validate proposed) mechanisms of resistance to anti-HER2 agents. The final purpose of these studies is twofold: to identify those patients who are less likely to respond to a given anti-HER2 therapy and to design ad hoc clinical trials testing new combinatorial therapeutic strategies for these resistant patients.